{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:27Z","timestamp":1793383167709,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Intestinal multidrug-resistant organism (MDRO) colonization is highly prevalent in long-term acute care hospital (LTACH) patients and is associated with MDRO infection and transmission. However, there are no therapies approved by the US Food and Drug Administration to reduce intestinal MDRO colonization.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the safety and acceptability of fecal microbiota transplantation (FMT) in LTACH patients.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This single-center, open-label nonrandomized clinical trial was conducted from April to December 2023 at an LTACH in the Southeastern US with median 50-patient census and 28-day length of stay. Patients with MDRO colonization were identified by perirectal prevalence sampling. Patients colonized with at least 1 target MDRO were approached for informed consent for FMT. FMT recipients were compared with untreated controls with MDRO colonization. Data were analyzed from August 2024 to May 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Healthy donor fecal microbiota (50-100 g stool and 250 mL normal saline with 9% glycerol) instilled via gastrostomy tube or enema without antibiotic or bowel preparation conditioning.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was frequency and severity of adverse events. Solicited adverse events were recorded for 7 days. Unsolicited adverse events were recorded for 6 months. Four weekly perirectal MDRO cultures were performed after FMT.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 42 patients, including 10 (mean [SD] age, 63.8 (14.5) years; 7 [70%] female) who received FMT and 32 contemporaneous controls (mean [SD] age, 64.0 [13.7] years; 13 [41%] female) were assessed. In 2 prevalence surveys, 23 of 32 (72%) and 26 of 34 (77%) perirectal cultures grew at least 1 MDRO. Among the FMT group, 5 patients received FMT via gastrostomy alone, 4 via enema alone, and 1 with both routes more than 30 days apart. No serious adverse events were attributed to FMT, and post-FMT solicited adverse events were mild. At final visit, all perirectal cultures from FMT recipients grew at least 1 MDRO. Post hoc analyses found numerically fewer FMT recipients had positive blood culture results (0 individuals vs 6 individuals [19%];\n P<\/jats:italic>\n \u2009=\u2009.31), pathogen intestinal dominance (2 of 8 individuals [25%] vs 4 of 8 individuals [50%];\n P<\/jats:italic>\n \u2009=\u2009.61), and 7 fewer days of antibiotic therapy per 1000 patient days (median [IQR], 12.6 [0-25.2] days vs 19.7 [6.5-36.1] days;\n P<\/jats:italic>\n \u2009=\u2009.38) compared with controls in the 6 months after prevalence survey, although these differences were not statistically significant. Accounting for higher baseline FMT recipient antibiotic use, difference-in-differences analysis estimated 26 (95% CI, \u221264 to 12) fewer days of antibiotic therapy per 1000 patient-days after FMT, although this difference was also not statistically significant.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this nonrandomized pilot clinical trial, FMT was acceptable for LTACH patients without related serious adverse events. Although not powered to test these outcomes, this study found potential reductions in bacteremia, intestinal pathogen domination, and antibiotic use associated with FMT, suggesting FMT should be evaluated in larger, randomized trials.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05780801<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.22740","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:31:09Z","timestamp":1753371069000},"page":"e2522740","source":"Crossref","is-referenced-by-count":12,"title":["Microbiota Transplantation Among Patients Receiving Long-Term Care"],"prefix":"10.1001","volume":"8","author":[{"given":"Michael H.","family":"Woodworth","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Babiker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Prakash-Asrani","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Christina","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Barrios","family":"Steed","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ashley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Koundakjian","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Acharya","sequence":"additional","affiliation":[{"name":"Emory Long Term Acute Care, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Grooms","sequence":"additional","affiliation":[{"name":"Emory Long Term Acute Care, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris W.","family":"Bower","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti R.","family":"Suchindran","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twinkle","family":"Trehan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Laufer","family":"Halpin","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroya","family":"Spalding Walters","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujan C.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Samore","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Claire","family":"Roghmann","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Van Riel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Burd","sequence":"additional","affiliation":[{"name":"Department of Pathology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lohsen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah W.","family":"Satola","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Fridkin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"10325","key":"zoi250664r1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"zoi250664r4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/cid\/ciy796","article-title":"Increased relative abundance of Klebsiella pneumoniae carbapenemase\u2013producing Klebsiella pneumoniae within the gut microbiota is associated with risk of bloodstream infection in long-term acute care hospital patients.","volume":"68","author":"Shimasaki","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi250664r5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/cis580","article-title":"Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation.","volume":"55","author":"Taur","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"zoi250664r6","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1038\/s41467-019-13467-w","article-title":"Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection.","volume":"10","author":"Magruder","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"zoi250664r7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/cid\/ciaa948","article-title":"Disease prevention not decolonization: a model for fecal microbiota transplantation in patients colonized with multidrug-resistant organisms.","volume":"72","author":"Ghani","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"720","key":"zoi250664r8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo2750","article-title":"Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement.","volume":"15","author":"Woodworth","year":"2023","journal-title":"Sci Transl Med"},{"issue":"8","key":"zoi250664r10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.cmi.2019.04.006","article-title":"Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review.","volume":"25","author":"Saha","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"zoi250664r11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.7326\/M18-3635","article-title":"Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study.","volume":"171","author":"Ianiro","year":"2019","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi250664r12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae309","article-title":"Recurrent Clostridioides difficile infection and outcome of fecal microbiota transplantation use: a population-based assessment.","volume":"11","author":"Mehta","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"zoi250664r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100906","article-title":"Pilot study of autologous fecal microbiota transplants in nursing home residents: feasibility and safety.","volume":"27","author":"Liu","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"zoi250664r15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2105\/AJPH.94.3.361","article-title":"Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement.","volume":"94","author":"Des Jarlais","year":"2004","journal-title":"Am J Public Health"},{"issue":"7","key":"zoi250664r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofz288","article-title":"The Role of fecal microbiota transplantation in reducing intestinal colonization with antibiotic-resistant organisms: the current landscape and future directions.","volume":"6","author":"Woodworth","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi250664r17","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1093\/cid\/ciaa737","article-title":"Oral capsulized fecal microbiota transplantation for eradication of carbapenemase-producing Enterobacteriaceae colonization with a metagenomic perspective.","volume":"73","author":"Bar-Yoseph","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi250664r18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/cid\/ciw185","article-title":"Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection.","volume":"62","author":"Millan","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi250664r19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.cmi.2018.12.009","article-title":"A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.","volume":"25","author":"Huttner","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"zoi250664r20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41591-022-01991-0","article-title":"Understanding and predicting the efficacy of FMT.","volume":"28","author":"Lavelle","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"zoi250664r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106216","article-title":"Bacterial diversity and specific taxa are associated with decolonization of carbapenemase-producing enterobacterales after fecal microbiota transplantation.","volume":"89","author":"Davido","year":"2024","journal-title":"J Infect"},{"issue":"4","key":"zoi250664r22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","article-title":"Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers.","volume":"30","author":"Dsouza","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"12","key":"zoi250664r23","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","article-title":"SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial.","volume":"72","author":"McGovern","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi250664r24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection.","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250664r25","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1805281","article-title":"Gut commensal microbiota and decreased risk for Enterobacteriaceae bacteriuria and urinary tract infection.","volume":"12","author":"Magruder","year":"2020","journal-title":"Gut Microbes"},{"issue":"1","key":"zoi250664r26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.chom.2023.11.016","article-title":"Fecal metabolite profiling identifies liver transplant recipients at risk for postoperative infection.","volume":"32","author":"Lehmann","year":"2024","journal-title":"Cell Host Microbe"},{"key":"zoi250664r2","doi-asserted-by":"crossref","DOI":"10.15620\/cdc:82532","volume-title":"Antibiotic Resistance Threats in the United States, 2019","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"zoi250664r3","unstructured":"Centers for Disease Control and Prevention; US Food and Drug Administration. Drug development considerations for the prevention of healthcare-associated infections. August 30, 2022. Accessed February 3, 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/drug-development-considerations-prevention-healthcare-associated-infections-08302022"},{"key":"zoi250664r9","doi-asserted-by":"crossref","unstructured":"Kwak? S, Choi? J, Hink? T, . The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.? Res Square. Preprint posted online March 13, 2020. . doi:10.21203\/rs.3.rs-17152\/v1","DOI":"10.21203\/rs.3.rs-17152\/v1"},{"key":"zoi250664r14","unstructured":"OpenBiome. 2022 Annual report: unlocking microbiome science for a healthier future. Accessed February 3, 2025. https:\/\/openbiome.org\/2022-annual-report\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2836786\/woodworth_2025_oi_250664_1752614674.29281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:31:10Z","timestamp":1753371070000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2836786"}},"subtitle":["The Sentinel REACT Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.22740","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]}}}